๐๐๐ข ๐ฆ๐ฎ๐ป ๐๐ถ๐ฒ๐ด๐ผ ๐ฝ๐ผ๐๐๐ ๐๐. ๐ฟ๐ฒ๐ฎ๐น๐ถ๐๐
LinkedIn version:
“Great discussions about the future of healthcare, breakthrough innovations, and exciting partnership opportunities.”
Actual version:
โ Coffee becoming a critical raw material
๐ฃ Walking miles between meetings in the convention center
๐ค Explaining cyclodextrins for the 37th time today (not a made-up number)
๐งฌ Discussing everything from biologics and RNA therapies to personalized medicine
๐ก Realizing that cyclodextrins are showing up in places nobody imagined 10 years ago
๐
Trying to remember whether this conversation was at Booth #1532, a networking reception, or while standing in line for coffee
What strikes me most at BIO this year is how much the conversation around cyclodextrins has evolved.
Not long ago, most discussions focused on solubility enhancement and formulation challenges. Today, we’re talking about cyclodextrins as active ingredients, enabling technologies for biologics, targeted delivery systems, and even personalized therapeutic approaches.
Trade shows are exhausting. The feet hurt, the voice gets tired, and the calendar becomes a blur of back-to-back meetings.
But every now and then, a conversation makes you stop and think:
“Wait… could cyclodextrins actually play a role there too?”
And that’s usually when the most interesting ideas start.
To everyone exhibiting, networking, pitching, partnering, and surviving BIO this week: I see you. ๐
